Since GPR40 is considered as a therapeutic target for T2DM and NAFLD is a T2DM complication, it is important to determine the role of GPR40 in pathogenesis of NAFLD. Here, FFAR1 is linked to metabolic dysfunction-associated steatotic liver disease.